Answers are grounded in this paper and cite their sources.
The proposal of proceeding to radical prostatectomy without histological confirmation represents a departure from long-established prostate cancer pathways, where biopsy is the gold standard, and reflects the advances of multiparametric-MRI (mpMRI) and prostate specific membrane antigen-positron emission tomography (PSMA-PET) in detecting clinically significant disease. Yang et al1 report outcomes of biopsy-free radical prostatectomy (BF-RP) compared with conventional surgery, suggesting comparable oncologic control and shorter length of stay. Their findings highlight the appeal of bypassing biopsy-related morbidity, including infection, hemorrhage, and peri-prostatic fibrosis that may compromise surgical planes. Yet, enthusiasm must be tempered. This study offered BF-RP based on PSA and mpMRI; however, mpMRI can miss 10% of significant cancers and is limited by its positive predictive value (PPV) of 36% to 69%.2 In this series, 1.8% of men had benign histology (4.6% had ISUP1 disease) despite rigorous selection. This presents a group of patients who were overtreated or not given the option of active surveillance. Each case of overtreatment carries profound implications: men subjected to major surgery with its significant risks for benign disease strikes at the core of our ethical responsibility to do no harm. Strict diagnostic algorithms integrating mpMRI with PSMA-PET have improved accuracy with a PPV of 100% reported for clinically significant cancer when both modalities detected a lesion.3 Although this suggests BF-RP could be viable in highly selected patients, we must weigh what is lost without biopsy. Histology provides genomic and pathological detail that guides nerve-sparing, lymph node dissection, and multimodal planning. Without it, surgeons operate with less certainty, risking less individualized care. BF-RP should be regarded as a hypothesis demanding rigorous prospective validation. Only trials with long-term outcomes can establish whether safety, efficacy, and cost-effectiveness justify dismantling biopsy's central role. Crucially, such evidence will allow patients to make informed choices about the risks and benefits of biopsy—or its omission—in shared decision making.
No takes yet. Share an insight, caveat, or question.
Palma et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: